There are some exciting developments in the biotech arena that could potentially be game-changers in their respective fields.

Initial public offerings do not always deserve the bad rap they get. Here are three reasons why they are worth a second look.

Will dividend caps be in place for much longer, or are we well on track for some kind of normalcy?

We look at what you need to know about Peter Lynch’s six categories of companies.

Practice can make your investment aim better over time.

We continue this week’s round-up with one of Singapore’s three big banks and two overseas REITs.